[The laboratory evaluation of dynamics of progression of liver fibrosis under chronic hepatitis].
The study was carried out to evaluate velocity of development of fibrosis of liver in patients with chronic hepatitis C using laboratory tests. The sampling of 150 patients with chronic hepatitis C were examined to analyze blood serum in phase of reactivation detecting concentration of hyaluronic acid, alpha-fetoprotein, iron, ferritin, vascular endothelial risk factor, malonic dialdehyde and activity of catalase. The degree of fibrosis of liver was evaluated using technique of ultrasound elastography. The velocity of development of fibrosis of liver was calculated as ratio of fibrosis (in points) to duration of infection (in years). The velocity of development of fibrosis of liver in group with slow rate of progression of disease made up in average 0.01±0.04 points per year and in the group with fast rate of progression of chronic hepatitis C - 0.45±0.34 points per year (p<0.001). In the group of patients with high velocity of development of fibrosis of liver were registered reliably higher values of density of liver (p<0.001). The fast velocity of development of fibrosis of liver was accompanied by increasing of serum concentrations of hyaluronic acid (p<0.001), alpha-fetoprotein (p=0.04), iron (p=0.03), ferritin (p=0.03) and decreasing of activity of catalase (p=0.04). The correlation analysis substantiated availability of reliable direct relationships of rate of progression of fibrosis with duration of disease (r=0.27, p=0.01), density of liver (r=0.86; p<0.001), hyaluronic acid (r=0.59; p<0.001), alpha-fetoprotein (r=0.23; p=0.04), ferritin (r=0.23; p=0.04), vascular endothelial risk factor (r=0.21; p=0.04). The association of increased serum levels of hyaluronic acid, alpha-fetoprotein, vascular endothelial risk factor, iron, ferritin and low activity of catalase with fast velocity of development of fibrosis of liver can be recommended as additional criteria of evaluation of rate of progression of fibrosis under chronic hepatitis C.